Stocktwits on MSN
REPL ignites on doctor fury against FDA’s melanoma drug snub — health sec steps back
FDA refused to approve Replimune’s melanoma drug RP1 for the second time earlier this month citing insufficient data to ...
InvestorsHub on MSN
Replimune plunges after second FDA setback for melanoma therapy; analysts turn bearish
Shares of Replimune Group (NASDAQ:REPL) tumbled sharply in premarket trading on Monday, falling close to 60% after the U.S.
At a Senate hearing, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Wednesday that he "had nothing to ...
Replimune (REPL) stock plunged 19% after FDA issued second rejection of RP1 melanoma immunotherapy, citing inadequate trial design and controls.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Replimune Group, Inc. stock drops after a second FDA rejection for RP1 melanoma; cash runway <12 months. Click for more on ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
An online coding platform called Repl.it is picking up popularity among kids and teenagers, who are using the platform to learn to code and to build apps online. Kids enjoy using Repl.it because they ...
REPL EFFECT: Repl.it, an online programming and computing platform, has raised $4.5 million in a seed round led by two general partners, Marc Andreessen and Andrew Chen, from the venture capital firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results